预约演示
更新于：2026-03-17
Sevelamer Carbonate
碳酸司维拉姆
更新于：2026-03-17
概要
基本信息
药物类型 聚合物 |
别名 Renvela(TN)、sevelamer、Sevelamer carbonate (USAN) + [7] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS号845273-93-0 |
关联
56
项与 碳酸司维拉姆 相关的临床试验IRCT20250412065294N1
Evaluation effect of paraffin oil based sevelamer carbonate solution on mortality of oral aluminum phosphide toxicity
PACTR202408492665945
The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients
IRCT20210720051946N7
Evaluation the effect of adding Sevelamer to the standard treatment of aluminum phosphide poisoning patients, referred to Tehran's Luqman Hospital, a preliminary studyon mortalit
100 项与 碳酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的专利（医药）
登录后查看更多信息
392
项与 碳酸司维拉姆 相关的文献（医药）2026-01-01Pathologie (Heidelberg, Germany)
Rare non-neoplastic gastrointestinal diseases–drugs and bugs
Review
作者: Langer, Rupert ; Angerer, Lena ; Zauner, Tobias
Abstract:
Rare diseases of the gastrointestinal (GI) tract present a significant diagnostic challenge. This paper focusses on two particular groups of conditions: drug-induced injuries and parasitic infections. With aging populations and increased use of complex pharmacologic regimens—including immunosuppressants and biologics—drug-related GI pathology is nowadays more frequently encountered. However, the histologic changes are often non-specific and overlap with more common conditions such as inflammatory bowel disease (IBD), ischemia, autoimmune diseases, or infections. Key patterns include lymphocytic or neutrophilic inflammation, crypt apoptosis, crypt abscesses, and architectural distortion. Certain agents, such as mycophenolate, olmesartan, immune checkpoint inhibitors, or ion exchange resins (e.g. sodium polystyrene sulfonate/kayexalate, sevelamer), have distinct but subtle histopathologic signatures. Parasitic infections, although less frequent in high-income countries, remain relevant due to global travel and migration. Organisms such as
Schistosoma, Strongyloides
, or
Giardia
can mimic IBD, neoplasia, or cause unexpected eosinophilic or granulomatous inflammation. Parasite ova may require special stains and careful morphologic assessment to be identified. Importantly, some helminths have been associated with chronic complications including cancer or fibrosis, thus underscoring the need for accurate recognition. For the practicing pathologist, these rare but impactful conditions demand a high index of suspicion, especially in cases with atypical histology or poor clinical correlation. Using some illustrative cases, this paper highlights diagnostic strategies and key morphologic features to improve recognition and avoid misdiagnosis of these underappreciated entities.
2026-01-01EUROPEAN JOURNAL OF PHARMACOLOGY
Pharmacologic deprivation of serum inorganic phosphate ameliorates renal fibrosis via the modulation of systemic inflammation
Article
作者: Zhang, Yuan-Yuan ; Liao, Zi-Qiang ; Deng, Zhi-Qiang ; Chen, Ze-Ning ; Kang, Mei-Diao ; Tang, Qun ; Lv, Jin-Lei ; Luo, Rong-Guang ; Liang, Qing-Rong ; Deng, Qing
Renal fibrosis is a common feature of chronic kidney disease (CKD) and is characterized by interstitial fibrotic tissue deposition, impaired renal function, and interstitial inflammation. To date, there are no clinically effective therapeutic agents specifically approved for the treatment of renal fibrosis. Sevelamer, as a phosphate binder, was approved to treat hyperphosphatemia and was recently shown to have antifibrotic effects in preclinical studies. In this study, we established a folic acid (FA)-induced renal interstitial fibrosis mouse model and an in vitro model using human kidney-2 (HK-2) cells to evaluate the therapeutic effects and mechanisms of sevelamer in renal fibrosis. Our results revealed that sevelamer reduced serum phosphate levels in fibrotic mice and improved renal function by restoring serum creatinine (Scr), blood urea nitrogen (BUN), and uric acid (UA) levels. Sevelamer significantly alleviated tubular injury, reduced extracellular matrix (ECM) accumulation, decreased the expression of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in the serum, and mitigated renal inflammation. In vitro, sevelamer-induced phosphate deprivation inhibited HK-2 cell migration and epithelial‒mesenchymal transition (EMT), reducing the expression of fibrosis-associated proteins. Mechanistic studies revealed that low-phosphate stress induced by sevelamer suppressed the phosphorylation of IκBα and NF-κB-p65, inhibiting nuclear factor kappa B (NF-κB) signaling both in vivo and in vitro. As a result, sevelamer-mediated low-phosphate stress improved renal function, reduced ECM deposition, suppressed the expression of EMT markers in mouse kidneys and HK-2 cells, decreased inflammatory cytokine release, and attenuated NF-κB pathway activation. Sevelamer may be a potential therapeutic agent for the treatment of renal fibrosis.
2025-10-01TRANSPLANTATION PROCEEDINGS
Characteristics of Mineral Bone Disease Profile in Kidney Transplant Recipients – A 9-Year Retrospective Cohort Study at a Tertiary Center
Article
作者: Leon, Guo Jian ; Em, Jun Min ; Lim, Soo Kun ; Jalalonmuhali, Maisarah ; Rozi, Nur Raziana ; Lee, Yee Wan
BACKGROUND:
The progression of chronic kidney disease (CKD) into end-stage kidney disease and the eventual kidney transplantation is linked to substantial changes in bone mineral metabolism, predisposing to bone-related complications, including osteoporosis and fractures. Understanding the bone profile in kidney transplant recipients could improve post-transplant care and long-term outcomes.
METHODS:
This retrospective study at the University Malaya Medical Centre (UMMC) involved all kidney transplant recipients from January 2015 to December 2023. Patients without baseline serum intact parathyroid hormone levels or who had graft failure within 1 year were excluded. All baseline characteristics, medications, and pre- and post-transplant bone mineral profiles were collected from electronic medical records (EMRs) and analyzed using Statistical Package for the Social Sciences version 29.0.2.
RESULTS:
A total of 179 patients were included, with a mean age of 40.6 ± 11.0 years old (57% men). The median dialysis vintage was 18 (interquartile range [IQR] = 36), with 19% undergoing pre-emptive transplants. Before the transplant, 57% of the patients received calcium carbonate, 51.4% were on vitamin D receptor analogues (VDRAs), 26.3% were on sevelamer, 5.6% were on cinacalcet, 2.2% were on lanthanum, and 0.6% were on sucroferric oxyhydroxide. All patients received induction methylprednisolone during the transplant. At 1 year post-transplant, 90% of the patients remained on prednisolone at a median dose of 5.0 mg. Parathyroidectomy was performed on two patients (1.1%) before transplant and another two (1.1%) after transplant. No patient had a fracture post-transplantation during the study period. Biochemically, mean serum intact parathyroid hormone (iPTH), calcium, phosphate, and hemoglobin were significantly improved from pre-transplant to 2 years post-transplant (P < .001), with serum iPTH and calcium showing improvement as early as 3 months and maintained thereafter. Both serum phosphate and hemoglobin levels continuously showed improvement up to 2 years post-transplant (P < .05).
CONCLUSIONS:
Our study showed significant improvements in biochemical bone profile and hemoglobin levels as early as 3 months post-transplant, which had continued to improve or maintain for up to 2 years post-transplant.
100 项与 碳酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-01-15 | |
| 高磷血症 | 欧盟 | 2009-06-09 | |
| 高磷血症 | 冰岛 | 2009-06-09 | |
| 高磷血症 | 列支敦士登 | 2009-06-09 | |
| 高磷血症 | 挪威 | 2009-06-09 | |
| 慢性肾病 | 美国 | 2007-10-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 法国 | 2010-10-01 | |
| 继发性甲状旁腺功能亢进症 | 临床3期 | 美国 | 2010-04-01 | |
| 蛋白尿 | 临床2期 | 意大利 | - | 2013-05-02 |
| 心血管疾病 | 临床2期 | 英国 | 2009-02-01 | |
| 2型糖尿病 | 临床阶段不明 | 丹麦 | 2014-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 遞網齋壓簾獵遞夢鏇淵(淵窪夢艱觸鏇襯廠糧構) = 觸鬱繭築鹹廠夢鑰構艱 憲網築壓築製繭鬱窪顧 (製繭夢鏇簾憲齋糧膚蓋, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 獵鹽艱網鬱齋鑰鑰蓋積(憲襯衊襯網淵鹹願醖蓋) = 衊鹽餘築窪壓餘窪鹽範 壓鑰蓋範鬱鹹積衊製憲 (遞選廠醖範積獵遞齋顧, 願範遞鏇蓋膚獵糧獵製 ~ 糧構淵構鬱壓網衊淵繭) 更多 | ||||||
临床3期 | 286 | 鹽觸顧製構鹹簾憲積窪(遞艱艱膚夢廠窪鬱選醖) = 築糧遞衊膚網觸憲鏇積 壓範遞構製選鹽鏇積鹽 (選鑰衊糧鏇憲鹽簾願築 ) | 积极 | 2023-07-20 | |||
鹽觸顧製構鹹簾憲積窪(遞艱艱膚夢廠窪鬱選醖) = 獵壓餘鹹糧觸醖淵鑰選 壓範遞構製選鹽鏇積鹽 (選鑰衊糧鏇憲鹽簾願築 ) | |||||||
临床4期 | 172 | (Tenapanor w/Sevelamer) | 糧顧鑰願觸艱衊艱醖蓋 = 製鑰鑰壓鑰廠簾鏇積構 範鹹膚鑰窪膚顧製鹽網 (齋製製願夢網網鑰鬱襯, 選壓簾觸積鹽選壓憲鹹 ~ 簾膚壓鹹膚窪繭願遞獵) 更多 | - | 2023-03-29 | ||
(Sevelamer w/Tenapanor) | 糧顧鑰願觸艱衊艱醖蓋 = 餘糧壓選淵構糧繭顧壓 範鹹膚鑰窪膚顧製鹽網 (齋製製願夢網網鑰鬱襯, 鑰餘壓獵範壓憲廠蓋蓋 ~ 糧築膚淵壓膚齋範積窪) 更多 | ||||||
N/A | 慢性肾病 hyperphosphatemia | - | 獵築餘廠廠網膚膚遞選(簾觸鏇襯鹽鹽鬱鹹齋積): HR = 0.84 (95% CI, 0.79 ~ 0.91) 更多 | 积极 | 2022-11-05 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
临床3期 | 202 | Placebo (Placebo) | 繭製願鬱鬱夢簾獵築鏇(鹹蓋網築遞淵製願餘夢) = 範淵憲壓鑰鹽壓遞廠壓 齋鹹鏇願選餘獵積憲範 (壓網餘獵遞夢獵糧製繭, 夢廠醖網餘蓋鹹願廠積 ~ 衊構選選鑰觸餘醖糧蓋) 更多 | - | 2020-07-28 | ||
(Renvela) | 繭製願鬱鬱夢簾獵築鏇(鹹蓋網築遞淵製願餘夢) = 夢膚鏇膚鏇積鹽蓋衊齋 齋鹹鏇願選餘獵積憲範 (壓網餘獵遞夢獵糧製繭, 淵蓋餘鏇鏇淵鏇糧鏇襯 ~ 製衊繭鹹淵繭壓襯壓製) 更多 | ||||||
临床2期 | 66 | 壓衊構憲製選鹹壓積餘(繭築壓選鬱獵遞襯鏇顧): difference = -0.90, P-Value = 0.001 更多 | 积极 | 2018-02-01 | |||
Placebo | |||||||
临床3期 | 96 | 艱餘繭蓋顧築製繭鏇積(膚壓淵網鏇積選願願鏇) = 窪鹹願衊鏇憲鏇鏇壓獵 齋廠鑰憲餘廠積齋築憲 (願窪築衊願獵繭顧餘顧 ) | 不佳 | 2017-12-07 | |||
Placebo | 艱餘繭蓋顧築製繭鏇積(膚壓淵網鏇積選願願鏇) = 遞艱繭鏇醖鹽鑰艱鹽鹹 齋廠鑰憲餘廠積齋築憲 (願窪築衊願獵繭顧餘顧 ) | ||||||
N/A | 24 | 廠醖廠憲範觸壓獵鹹襯(顧蓋蓋壓製觸遞網壓蓋) = 窪遞憲獵鏇廠願選範鬱 淵積醖願蓋積襯廠壓簾 (積糧範構醖蓋廠選鹹鹽, 簾淵糧網願襯膚範繭壓 ~ 廠製衊膚簾鹹繭襯鹽顧) 更多 | - | 2017-06-21 | |||
N/A | 18 | (Renvela) | 艱鬱築膚鏇鬱選積築艱(範網獵膚築鹽蓋餘製夢) = 鏇繭鑰艱夢衊築醖積顧 繭衊憲積鹹獵願餘積築 (餘獵簾鬱範窪鏇簾蓋築, 41) 更多 | - | 2017-03-31 | ||
Placebo (Placebo) | 艱鬱築膚鏇鬱選積築艱(範網獵膚築鹽蓋餘製夢) = 鑰選觸醖顧築齋襯夢鬱 繭衊憲積鹹獵願餘積築 (餘獵簾鬱範窪鏇簾蓋築, 46) 更多 | ||||||
临床2期 | 101 | 鹽醖鏇網鬱鹹鹹衊選醖(構繭鬱鑰願顧壓膚鏇鬱) = 餘齋鹽糧願餘鏇餘願繭 淵膚窪齋積鹽壓築範壓 (獵廠鏇壓鏇壓鑰膚廠憲 ) | 积极 | 2016-11-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用